Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
Emergent BioSolutions (NYSE: EBS) reaffirms its commitment to combating the opioid epidemic by expanding access to NARCAN® Nasal Spray and educating the public on opioid overdose response. The company is supporting the 'White House Challenge to Save Lives from Overdose' by implementing workplace safety measures and continuing its Ready to Rescue public awareness campaign.
Emergent has installed opioid emergency wall units in its facilities and provided NARCAN® Nasal Spray to employees. The company is also working with partners like the National Safety Council to educate businesses. Since NARCAN® Nasal Spray became available over the counter in August 2023, Emergent has distributed over 2,700 opioid emergency kits on college campuses and in public venues.
In response to recent CDC data showing a decline in opioid overdose deaths, Emergent is pledging to donate an additional 20,000 doses of NARCAN® Nasal Spray to communities in need. The company remains committed to expanding access and awareness through OTC availability, partnerships, and education initiatives.
Emergent BioSolutions (NYSE: EBS) riafferma il suo impegno nella lotta contro l'epidemia di oppioidi ampliando l'accesso allo NARCAN® Nasal Spray e educando il pubblico sulla risposta all'overdose da oppioidi. L'azienda sostiene la 'Sfida della Casa Bianca per Salvare Vite dalle Overdose' attuando misure di sicurezza sul posto di lavoro e continuando la sua campagna di sensibilizzazione pubblica Ready to Rescue.
Emergent ha installato unità di emergenza per oppioidi nelle proprie strutture e ha fornito NARCAN® Nasal Spray ai dipendenti. L'azienda sta anche collaborando con partner come il National Safety Council per educare le aziende. Dalla disponibilità di NARCAN® Nasal Spray senza ricetta nel agosto 2023, Emergent ha distribuito oltre 2.700 kit di emergenza per oppioidi nei campus universitari e in luoghi pubblici.
In risposta ai recenti dati del CDC che mostrano una diminuzione dei decessi per overdose da oppioidi, Emergent si impegna a donare ulteriori 20.000 dosi di NARCAN® Nasal Spray alle comunità bisognose. L’azienda rimane impegnata ad ampliare l’accesso e la consapevolezza tramite la disponibilità OTC, le collaborazioni e le iniziative educative.
Emergent BioSolutions (NYSE: EBS) reafirma su compromiso en la lucha contra la epidemia de opioides al ampliar el acceso a NARCAN® Nasal Spray y educar al público sobre cómo responder a las sobredosis de opioides. La compañía está apoyando el 'Desafío de la Casa Blanca para Salvar Vidas de Sobredosis' implementando medidas de seguridad en el lugar de trabajo y continuando su campaña de concienciación pública Ready to Rescue.
Emergent ha instalado unidades de emergencia para opioides en sus instalaciones y ha proporcionado NARCAN® Nasal Spray a los empleados. La compañía también está trabajando con socios como el Consejo Nacional de Seguridad para educar a las empresas. Desde que NARCAN® Nasal Spray se volvió disponible sin receta en agosto de 2023, Emergent ha distribuido más de 2,700 kits de emergencia para opioides en campus universitarios y lugares públicos.
En respuesta a datos recientes de los CDC que muestran una disminución en las muertes por sobredosis de opioides, Emergent se compromete a donar 20,000 dosis adicionales de NARCAN® Nasal Spray a comunidades necesitadas. La compañía sigue comprometida a ampliar el acceso y la conciencia a través de la disponibilidad OTC, asociaciones e iniciativas educativas.
Emergent BioSolutions (NYSE: EBS)는 NARCAN® Nasal Spray의 접근성을 확대하고 오피오이드 과다복용 대응에 대한 대중 교육을 통해 오피오이드 전염병에 맞서는 노력을 재확인했습니다. 회사는 직장 내 안전 조치를 시행하고 Ready to Rescue 공공 인식 캠페인을 지속하여 '과다복용으로부터 생명을 구하는 백악관 챌린지'를 지원하고 있습니다.
Emergent는 시설에 오피오이드 응급 대책으로 벽면 유닛을 설치하고 직원들에게 NARCAN® Nasal Spray를 제공했습니다. 이 회사는 기업 교육을 위해 National Safety Council과 같은 파트너들과 협력하고 있습니다. 2023년 8월부터 NARCAN® Nasal Spray가 의약품 외 처방으로 제공된 이후, Emergent는 대학 캠퍼스와 공공 장소에서 2,700개 이상의 오피오이드 응급 키트를 배포했습니다.
최근 CDC 데이터에 따르면 오피오이드 과다복용 사망자가 감소했다고 하여, Emergent는 도움이 필요한 커뮤니티에 추가 20,000 도즈를 기부할 것을 약속하고 있습니다. 이 회사는 OTC 접근성, 파트너십 및 교육 이니셔티브를 통해 접근성과 인식을 확대하겠다는 약속을 지속하고 있습니다.
Emergent BioSolutions (NYSE: EBS) réaffirme son engagement dans la lutte contre l'épidémie d'opioïdes en élargissant l'accès au NARCAN® Nasal Spray et en éduquant le public sur la réponse aux overdoses d'opioïdes. L'entreprise soutient le 'Défi de la Maison Blanche pour Sauver des Vies par Rapport aux Overdoses' en mettant en place des mesures de sécurité au travail et en poursuivant sa campagne de sensibilisation publique Ready to Rescue.
Emergent a installé des unités d'urgence pour opioïdes dans ses établissements et a fourni du NARCAN® Nasal Spray à ses employés. L'entreprise collabore également avec des partenaires tels que le National Safety Council pour éduquer les entreprises. Depuis que le NARCAN® Nasal Spray est disponible sans ordonnance depuis août 2023, Emergent a distribué plus de 2 700 kits d'urgence pour opioïdes sur les campus universitaires et dans des lieux publics.
En réponse aux données récentes des CDC montrant une baisse des décès par overdose d'opioïdes, Emergent s'engage à donner 20 000 doses supplémentaires de NARCAN® Nasal Spray aux communautés dans le besoin. L'entreprise reste engagée à élargir l'accès et la sensibilisation grâce à la disponibilité OTC, à des partenariats et à des initiatives éducatives.
Emergent BioSolutions (NYSE: EBS) bekräftigt sein Engagement im Kampf gegen die Opioid-Epidemie, indem es den Zugang zu NARCAN® Nasal Spray erweitert und die Öffentlichkeit über das richtige Vorgehen bei Opioid-Überdosierungen aufklärt. Das Unternehmen unterstützt die 'White House Challenge to Save Lives from Overdose', indem es Sicherheitsmaßnahmen am Arbeitsplatz implementiert und seine Ready to Rescue Kampagne zur öffentlichen Sensibilisierung fortsetzt.
Emergent hat in seinen Einrichtungen Notfalleinheiten für Opioide installiert und den Mitarbeitern NARCAN® Nasal Spray zur Verfügung gestellt. Das Unternehmen arbeitet auch mit Partnern wie dem National Safety Council zusammen, um Unternehmen zu schulen. Seit NARCAN® Nasal Spray im August 2023 rezeptfrei erhältlich ist, hat Emergent über 2.700 Notfall-Kits für Opioide auf Universitätsgeländen und in öffentlichen Einrichtungen verteilt.
In Reaktion auf aktuelle CDC-Daten, die einen Rückgang der Todesfälle durch Opioid-Überdosierung zeigen, verpflichtet sich Emergent, zusätzlich 20.000 Dosen von NARCAN® Nasal Spray an bedürftige Gemeinschaften zu spenden. Das Unternehmen bleibt entschlossen, den Zugang und das Bewusstsein durch OTC-Verfügbarkeit, Partnerschaften und Bildungsinitiativen zu erweitern.
- None.
- None.
- Ongoing support of the ‘White House Challenge to Save Lives from Overdose’ through workplace and public safety measures
- One-year mark of Ready to Rescue public awareness campaign to expand awareness, particularly among young adults and vulnerable communities
- 20,000 additional doses of NARCAN® Nasal Spray to be donated to organizations in need
GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emergent is working with businesses to prepare for accidental opioid emergencies by ensuring workplaces, facilities, and hospitality venues, among many other locations, should consider being equipped with NARCAN® Nasal Spray. In March 2024, Emergent joined the ‘White House Challenge to Save Lives from Overdose’, a nationwide call encouraging leaders to commit to increasing education of and access to life-saving opioid overdose reversal medications.
“Businesses across the country, including many large employers, are taking thoughtful steps to respond to the national opioid epidemic,” said Joe Papa, president and chief executive officer of Emergent. “We applaud the White House and all organizations that have stepped up to join the broader effort to combat against opioid overdose deaths, which are occurring far too often.”
As part of its commitment to the White House’s Challenge, Emergent has installed more than 40 opioid emergency wall units near first aid stations and AEDs in its offices and facilities and provided over 1,300 cartons of NARCAN® Nasal Spray to its employees this year. In line with Emergent’s mission to expand access, awareness and availability, it is engaging with partners, including the National Safety Council (NSC*), to educate and reach businesses.
In August 2023, NARCAN® Nasal Spray became available over the counter (OTC) and shortly after, Emergent’s national awareness campaign, Ready to Rescue, launched to break down the stigma around opioid use and accidental overdose. Since then, Emergent has handed out more than 2,700 opioid emergency kits containing one carton of NARCAN® Nasal Spray and educational resources across several college campuses and public venues.
In addition, recent preliminary data from the Centers for Disease Control and Prevention (CDC) has pointed to a meaningful decline in opioid overdose deaths in the U.S. for the first time in decades.2 Naloxone, the active ingredient in NARCAN® Nasal Spray, is a life-saving medication that can reverse an overdose from opioids, including heroin, fentanyl, and prescription opioid medications, when given in time.
Papa stated, “Today, we are pledging to make an additional donation of 20,000 doses of NARCAN® Nasal Spray to help communities in need. It is promising to see the recent decline in opioid overdose deaths for the first time in years, and while we are pleased to see this progress, now is not the time to lose momentum. Emergent remains committed to playing our part in bringing down the number of opioid-related deaths by continuing to expand access efforts through the OTC availability of NARCAN® Nasal Spray, working closely with our public interest partners and advocates on the frontlines, as well as increasing education through our Ready to Rescue campaign, because we believe even one overdose death is unacceptable.”
Opioid emergencies can happen anytime, anywhere and to anyone.3 Increasing access and awareness to opioid overdose reversal treatments like NARCAN® Nasal Spray is a key component among a mix of interventions helping to curb the number of lives lost each year. Continued advocacy for comprehensive strategies that include the provision of NARCAN® Nasal Spray, prevention, treatment and recovery support efforts are essential to sustain and improve upon these reductions in death rates. With more than 80,000 American lives lost each year4 due to an opioid overdose, expanding access to life-saving treatments like NARCAN® Nasal Spray and providing education on how to administer it are essential to helping prepare individuals.
Learn more about how you can access NARCAN® Nasal Spray and be prepared to save a life at NARCAN.com.
*As a contracted commercial partner of Emergent, NSC will receive a fee for service.
About NARCAN® Nasal Spray
NARCAN® Nasal Spray is a pure opioid antagonist indicated for emergency use to reverse known or suspected opioid overdose, as manifested by respiratory and/or severe central nervous system depression.
While NARCAN® Nasal Spray can be administered by a non-health care professional, it is not intended to be a substitute for professional medical care. Always call 911 as soon as an opioid overdose is suspected and before administering NARCAN® Nasal Spray. Always read the label and follow the directions for use.
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statements will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
References:
- U.S. Department of Labor, Bureau of Labor Statistics, in cooperation with state, New York City, District of Columbia, and federal agencies. Census of Fatal Occupational Injuries. https://www.bls.gov/news.release/pdf/cfoi.pdf. Accessed October 7, 2024.
- Centers for Disease Control and Prevention. Provisional Drug Overdose Death Counts. Updated September 11, 2024. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Accessed September 26, 2024.
- Centers for Disease Control and Prevention. Preventing an Opioid Overdose Know the Signs Save a Life. https://www.cdc.gov/drugoverdose/pdf/patients/Preventing-an-Opioid-Overdose-Tip-Card-a.pdf. Accessed September 26, 2024.
- Centers for Disease Control and Prevention. U.S. Overdose Deaths Decrease in 2023, First Time Since 2018. May 15, 2024. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm. Accessed September 26, 2024.
FAQ
What is Emergent BioSolutions (EBS) doing to combat the opioid epidemic?
How many additional doses of NARCAN® Nasal Spray is EBS donating?
When did NARCAN® Nasal Spray become available over the counter (OTC)?
How many opioid emergency kits has EBS distributed since NARCAN® Nasal Spray became OTC?
What recent trend has the CDC reported regarding opioid overdose deaths in the U.S.?
